Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eisai EMEA (Europe, Middle East, Africa, Russia and Oceania) has announces that Halaven (eribulin) is now commercially available in Lebanon as a treatment for women with locally advanced or metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease.
Subscribe to our email newsletter
Prior therapy should have included an anthracycline and a taxane unless patients were not suitable for these treatments. Eisai will partner with Abela Frères to market eribulin in Lebanon.
Eisai EMEA market development business unit vice president Toshitaka Asano noted that the launch of Halaven in Lebanon is part of Eisai’s wider strategy to establish a solid foundation in the EMEA region.
"Lebanon is an important market with specific healthcare needs and our valued partnership with Abela Frères will ensure that people with metastatic and locally advanced breast cancer have access to this additional and important treatment option," Asano added.